Peter D. Kies
Net Worth

Last updated:

What is Peter D. Kies net worth?

The estimated net worth of Mr. Peter D. Kies is at least $15,726,113 as of 15 May 2024. He owns shares worth $251,113 as insider, has earned $1,742,890 from insider trading and has received compensation worth at least $13,732,110 in Inovio Pharmaceuticals, Inc..

What is the salary of Peter D. Kies?

Mr. Peter D. Kies salary is $653,910 per year as Chief Financial Officer in Inovio Pharmaceuticals, Inc..

How old is Peter D. Kies?

Mr. Peter D. Kies is 62 years old, born in 1963.

What stocks does Peter D. Kies currently own?

As insider, Mr. Peter D. Kies owns shares in one company:

Company Title Shares Price per share Total value
Inovio Pharmaceuticals, Inc. (INO) Chief Financial Officer 130,788 $1.92 $251,113

What does Inovio Pharmaceuticals, Inc. do?

Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. The company engages in conducting and planning clinical studies of its DNA medicines for HPV-associated precancers, including cervical, vulvar, and anal dysplasia; HPV-associated cancers, such as head and neck, cervical, anal, penile, vulvar, and vaginal; other HPV-associated disorders, including recurrent respiratory papillomatosis; glioblastoma multiforme; prostate cancer; HIV; Ebola; Middle East Respiratory Syndrome (MERS); and Lassa fever. Its partners and collaborators include ApolloBio Corp., AstraZeneca, Beijing Advaccine Biotechnology Co., Ltd., The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations (CEPI), Defense Advanced Research Projects Agency (DARPA), Department of Defense (DoD), HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, Medical CBRN Defense Consortium (MCDC), National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Ology Bioservices, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Thermo Fisher Scientific, University of Pennsylvania, Walter Reed Army Institute of Research, and The Wistar Institute. The company has an agreement with Richter-Helm BioLogics GmbH & Co. KG to support investigational DNA vaccine INO-4800 for COVID-19; and a partnership with International Vaccine Institute and Seoul National University Hospital. The company was founded in 1979 and is headquartered in Plymouth Meeting, Pennsylvania.

INO logo
INO
Inovio Pharmaceuticals, Inc.
$1.92

Peter D. Kies insider trading

Inovio Pharmaceuticals, Inc.

Mr. Peter D. Kies has made 10 insider trades between 2004-2024, according to the Form 4 filled with the SEC.

The largest trade he's ever made was exercising 59,737 units of INO stock on 11 Mar 2021. As of 15 May 2024 he still owns at least 130,788 units of INO stock.

Transaction Date Security Shares Price per share Total value Source
Option
Common Stock 4,771 N/A N/A
Option
Restricted Stock Unit 4,771 N/A N/A
Option
Restricted Stock Unit 59,737 N/A N/A
Option
Common Stock 59,737 N/A N/A
Option
Restricted Stock Unit 59,737 N/A N/A
Option
Common Stock 59,737 N/A N/A
Option
Common Stock 21,466 N/A N/A
Option
Restricted Stock Unit 21,466 N/A N/A
Option
Common Stock 22,545 N/A N/A
Option
Restricted Stock Unit 22,545 N/A N/A
Option
Common Stock 13,750 $2.16 $29,700
Sale
Common Stock 33,750 $10.01 $337,838
Option
Common Stock Option 13,750 $2.16 $29,700
Sale
Common Stock 10,000 $8.03 $80,300
Sale
Common Stock 10,000 $8.52 $85,200
Option
Common Stock 59,737 N/A N/A
Option
Restricted Stock Unit 59,737 N/A N/A
Option
Common Stock 21,467 N/A N/A
Option
Restricted Stock Unit 21,467 N/A N/A
Option
Restricted Stock Unit 27,566 N/A N/A
Option
Common Stock 27,566 N/A N/A
Option
Common Stock 30,000 $4.56 $136,800
Sale
Common Stock 30,000 $4.56 $136,800
Option
Common Stock Option 30,000 N/A N/A
Option
Common Stock 20,000 N/A N/A
Sale
Common Stock 20,000 N/A N/A
Option
Common Stock Option 20,000 N/A N/A
Sale
Common Stock 35,000 N/A N/A
Option
Common Stock Option 35,000 N/A N/A
Option
Common Stock 35,000 N/A N/A
Sale
Common Stock 35,000 $26.5 $927,500
Option
Common Stock 20,433 N/A N/A
Option
Restricted Stock Unit 20,433 N/A N/A
Option
Restricted Stock Unit 21,467 N/A N/A
Option
Common Stock 21,467 N/A N/A
Option
Common Stock 27,567 N/A N/A
Option
Restricted Stock Unit 27,567 N/A N/A
Option
Common Stock 20,433 N/A N/A
Option
Restricted Stock Unit 20,433 N/A N/A
Option
Common Stock 25,000 $3.34 $83,500
Option
Restricted Stock Unit 25,000 $3.34 $83,500
Option
Restricted Stock Unit 27,567 N/A N/A
Option
Common Stock 27,567 N/A N/A
Option
Common Stock Option 10,001 $2 $20,002
Sale
Common Stock 10,001 $2 $20,002
Option
Common Stock 10,001 $2 $20,002
Sale
Common Stock 10,000 $4.45 $44,500
Option
Common Stock 15,000 $4.24 $63,600
Option
Common Stock Option 15,000 $4.24 $63,600
Sale
Common Stock 25,000 $4.43 $110,750
Option
Restricted Stock Unit 20,434 N/A N/A
Option
Common Stock 20,434 N/A N/A
Option
Common Stock 25,000 N/A N/A
Option
Restricted Stock Unit 25,000 N/A N/A
Option
Restricted Stock Unit 8,333 $4.29 $35,749
Option
Common Stock 8,333 $4.29 $35,749
Option
Common Stock 25,000 $6.68 $167,000
Option
Restricted Stock Unit 25,000 $6.68 $167,000
Option
Restricted Stock Unit 8,333 N/A N/A
Option
Common Stock 8,333 N/A N/A
Option
Common Stock 8,334 N/A N/A
Option
Restricted Stock Unit 8,334 N/A N/A
Purchase
Common Stock 3,960 $10.1 $39,996
Purchase
Common Stock 25,000 $0.41 $10,250
Purchase
Common Stock 18,000 $0.54 $9,630
Purchase
Common Stock 19,150 $0.51 $9,671
Purchase
Common Stock 24,000 $0.57 $13,632
Purchase
Genetronics Biomedical Series C Convertible Preferred Stock 1 $5,882.35 $5,882
Purchase
Genetronics Biomedical Corporation Common Stock Warrants 514 $8.8 $4,523

Inovio Pharmaceuticals key executives

Inovio Pharmaceuticals, Inc. executives and other stock owners filed with the SEC: